^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + BRAF V600E

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    1956; 673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over4years
    [VIRTUAL] Identification of targetable alterations using NGS-based liquid biopsy in NSCLC patients (ESMO 2020)
    Funding: This study was supported by CB16/12/00350 and P118/00226 from ISCIII and Asociación de Mujeres de Apoyo al Cáncer de Mama (AMACMA). AM is recipient of PhD scholarship from Asociación Española Contra el Cáncer (AECC) Valencia Scientific Foundation.
    Clinical • Liquid biopsy • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • CDK4 (Cyclin-dependent kinase 4)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • HER-2 amplification • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12V • EGFR L858R + EGFR T790M • KRAS G12 • EGFR mutation + BRAF V600E • EGFR mutation + KRAS mutation • BRAF mutation + MET amplification • EGFR T790M + KRAS mutation • EGFR exon 2-7 deletion + EGFR amplification • EGFR mutation + EGFR T790M
    |
    Oncomine™ Pan-Cancer Cell-Free Assay
    over4years
    [VIRTUAL] Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT) (ESMO 2020)
    Legal entity responsible for the study: Gustave Roussy. Funding: Gustave Roussy.
    Clinical • BRCA Biomarker • MSi-H Biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    BRAF V600E • EGFR mutation • MSI-H/dMMR • KRAS G12C • BRAF V600 • ALK rearrangement • KRAS G12 • EGFR mutation + BRAF V600E
    over4years
    Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. (PubMed, PLoS One)
    "Acquired T790M at TKI relapse was detected in 73% (46/63) of patients, and all prospective patients (34/46) initiated osimertinib treatment based on ctDNA results...ctDNA molecular profiling is an accurate and reliable tool for the detection of clinically relevant molecular alterations in advanced NSCLC patients. Clinical outcomes with targeted therapies endorse the use of liquid biopsy by amplicon-based NGS ctDNA analysis in first line and relapse testing for advanced NSCLC patients."
    Journal • Clinical
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • EGFR mutation + BRAF V600E • EGFR mutation + EGFR T790M
    |
    InVisionFirst®-Lung
    |
    Tagrisso (osimertinib)